Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Alabama: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (197 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 35 | 1,077 | 45% |
| 2020 | 26 | 820 | 49% |
| 2021 | 19 | 736 | 54% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 85% of the cases CMS names in Alabama; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 35 | 2,324−19%/yr | −19%/yr | 5.51.0× | 57% | 2,050 in 2030−2.1%/yr |
| Peripheral arterial intervention |
Carotid revascularization in every state, and its device makers · Every procedure market in Alabama · Every state · Compare with Florida
| 2024 |
| 604 |
| 64% |
| 2025 est. | ≈ 620 | – |
| 2026 est. | ≈ 610 | – |
| 2022 | 19 | 678 | 58% |
| 2023 | 17 | 652 | 62% |
| 2024 | 13 | 604 | 64% |
| 2025 from claims | – | 615 503–725 | 65% |
| 2026 forecast | – | 610 484–772 | 66% |
| 2027 forecast | – | 607 457–810 | 67% |
| 2028 forecast | – | 604 435–843 | 68% |
| 2029 forecast | – | 601 416–872 | 68% |
| 2030 forecast | – | 597 400–898 | 69% |
In 2025, 91% inpatient hospital, 9% hospital outpatient.
| −4.9%/yr |
| 1.4 |
| 0% |
| 3,270 in 2030+1.5%/yr |
| Georgia | 20 | 1,076−5%/yr | −5%/yr | 1.2 | 0% | 1,270 in 2030+2.7%/yr |
| Tennessee | 23 | 1,061−7.3%/yr | −7.3%/yr | 1.5 | 0% | 1,080 in 2030+0.3%/yr |
| Virginia | 28 | 1,020−4.3%/yr | −4.3%/yr | 1.0 | 0% | 1,230 in 2030+3.1%/yr |
| North Carolina | 17 | 906−10%/yr | −10%/yr | 0.9 | 0% | 930 in 2030+0.4%/yr |
| Maryland | 19 | 807+0.3%/yr | +0.3%/yr | 0.9 | 0% | 840 in 2030+0.6%/yr |
| Kentucky | 15 | 771−5.3%/yr | −5.3%/yr | 1.6 | 0% | 730 in 2030−1%/yr |
| South Carolina | 14 | 708−7.8%/yr | −7.8%/yr | 1.0 | 0% | 840 in 2030+2.9%/yr |
| Oklahoma | 16 | 708−5.9%/yr | −5.9%/yr | 1.4 | 0% | 650 in 2030−1.3%/yr |
| Louisiana | 17 | 673−7.7%/yr | −7.7%/yr | 1.6 | 0% | 580 in 2030−2.4%/yr |
| Arkansas | 13 | 519−9%/yr | −9%/yr | 1.4 | 0% | 530 in 2030+0.4%/yr |
| Mississippi | 11 | 449−8.3%/yr | −8.3%/yr | 1.2 | 0% | 340 in 2030−4.7%/yr |
| West Virginia | 5 | 368−6.9%/yr | −6.9%/yr | 1.7 | 0% | 340 in 2030−1.5%/yr |
| Delaware | 10 | 167−4.2%/yr | −4.2%/yr | 1.0 | 0% | 160 in 2030−0.6%/yr |
| 19 |
| 2,305−11%/yr |
| −11%/yr |
| 5.00.8× |
| 47% |
| 2,110 in 2030−1.4%/yr |
| Superficial venous ablation | 29 | 2,001−5.2%/yr | −5.2%/yr | 4.30.7× | 85% | 2,070 in 2030+0.6%/yr |
| Thrombectomy, IVC filters & venous stents | 7 | 700−3.6%/yr | −3.6%/yr | 1.60.9× | 12% | 680 in 2030−0.4%/yr |
| Aortic endografts (EVAR/TEVAR) | 2 | 201−11%/yr | −11%/yr | 0.51.1× | 0% | 210 in 2030+1%/yr |
Boston Scientific leads with 60% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 5 companies reported engagement with Alabama’s surgeons worth $5,058 in consulting, speaking, meals and travel tied to these products, about $389 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.